

Sulfated Galactans from Red Seaweed *Gracilaria fisheri* Target Epidermal Growth Factor Receptor (EGFR) and Inhibit Cholangiocarcinoma Cells (CCA) Proliferation

Thannicha Sae-lao

*Department of Anatomy, Faculty of Science, Mahidol University, Rama VI Road, Bangkok
10400, Thailand.*

Rutaiwan Thotong, Ph.D.

Department of Biochemistry, Faculty of Science, Mahidol University, Rama VI Road,
Bangkok 10400, Thailand.

David Bates, Ph.D.

Cancer Biology, Division of Cancer Stem Cells, School of Medicine, University of
Nottingham, Queen Medical Centre, Nottingham NG7 2UH, United Kingdom.

Kanokpan Wongprasert, Ph.D.

Department of Anatomy, Faculty of Science, Mahidol University, Rama VI Road, Bangkok
10400, Thailand.

Running title: Sulfated galactans inactivated EGFR and inhibited CCA proliferation

Numbers of pages: 24

Numbers of figures: 9

Number of tables: 1

Correspondence to: Kanokpan Wongprasert, Ph. D., Department of Anatomy, Faculty of
Science, Mahidol University, RamaVI Road, Bangkok 10400, Thailand

Phone: 662-201-5447, Fax: 662-354-7168

E-mail: kanokpan.won@mahidol.ac.th

1 **Abstract**

2 Cholangiocarcinoma (CCA) is increasing in incidence worldwide and is resistant to
3 chemotherapeutic agents, making treatment of CCA a major challenge. Previous studies
4 reported that natural sulfated polysaccharides (SPs) disrupted growth factor receptor
5 activation in cancer cells. The present study, therefore, aimed at investigating the anti-
6 proliferation effect of sulfated galactans (SG) isolated from the red seaweed *Gracilaria*
7 *fisheri* (*G. fisheri*) on CCA cell lines. Direct binding activity of SG to CCA cells, epidermal
8 growth factor (EGF) and epidermal growth factor receptor (EGFR) were determined. The
9 effect of SG on proliferation of CCA cells was investigated. Cell cycle analyses and
10 expression of signaling molecules associated with proliferation were also determined. The
11 results demonstrated that SG bound directly to EGFR. SG inhibited proliferation of various
12 CCA cell lines by inhibiting EGFR and extracellular signal-regulated kinases (ERK)
13 phosphorylation, and inhibited EGF-induced increased cell proliferation. Cell cycle analyses
14 showed that SG induced cell cycle arrest at the G₀/G₁ phase, down-regulated cell cycle genes
15 and proteins (cyclin-D, cyclin-E, Cdk-4, Cdk-2), and up-regulated the tumor suppressor
16 protein P53 and the cyclin-dependent kinase inhibitor P21. Taken together, these data
17 demonstrate that SG from *G. fisheri* inhibited proliferation of CCA cells, and its mechanism
18 of inhibition is mediated, to some extent, by inhibitory effects on EGFR activation and
19 EGFR/ERK signaling pathway. SG presents a potential EGFR targeted molecule, which may
20 be further clinically developed in a combination therapy for CCA treatment.

21

22 **Keywords:** Cholangiocarcinoma; EGFR; *Gracilaria fisheri*; Sulfated galactans; Anti-
23 proliferation

24

25

26

27 Introduction

28 Cholangiocarcinoma (CCA) is a malignant transformation of cholangiocytes, the epithelial
29 cells lining the biliary tree (Khan *et al.*, 2005). In the Northeastern part of Thailand, CCA is
30 associated with infection of the liver fluke, *Opisthorchis viverrini* (Sriamporn *et al.*, 2004;
31 Sripa *et al.*, 2011). The disease has a high fatality rate due to a combination of late diagnosis
32 and lack of treatment options (Tushar, 2002). Combinations of radiation and chemotherapy
33 are used in an attempt to improve survival of patients, but, these therapies have many side-
34 effects and in patients with metastatic or inoperable disease, survival is not significantly
35 improved (Benavides *et al.*, 2015). Current standard of care is gemcitabine and cisplatin, but
36 this only increased survival by 2-3 months in trials in the US and Europe, and data on trials in
37 Thailand is still missing.

38 Heparin-binding EGF-like growth factor (HB-EGF) is a member of epidermal growth
39 factor (EGF) family. Generally, it binds epidermal growth factor receptor (EGFR) using co-
40 receptor heparan sulfate proteoglycans (HSPGs) (Iwamoto *et al.*, 2010). CCA from various
41 sources have been shown to express the EGFR and other heparin sulfate binding growth
42 factors (Yoshikawa *et al.*, 2007; Hoffmann *et al.*, 2013; Clapéron *et al.*, 2014) and inhibition
43 of EGFR activation has been shown to prevent growth of CCA cells in vitro. However, a
44 clinical trial of the EGFR antibody panitumumab, carried out on patients in Europe did not
45 find any effect of EGFR inhibition on patient survival. A number of new trials are ongoing in
46 Europe and the US, including a combination of gemcitabine and cisplatin, with vandetanib
47 (Kessler *et al.*, 2016), an antagonist to EGFR and vascular endothelial growth factor receptor
48 (VEGFR). Vandetanib has also been shown to decrease the growth of human CCA cell lines
49 (Yoshikawa *et al.*, 2009). These results indicate that heparin-binding growth factors such as
50 EGF and vascular endothelial growth factor (VEGF) could play a role in cholangiocarcinoma

51 progression and could be potential targets for therapy. However, all these trials, and most of
52 the cell biology is undertaken on CCA from European and US patients, which have been
53 shown to be drastically different in their biology from CCA from Thai patients. The
54 molecular etiology of *Opisthorchis* related CCA has recently been shown to be different from
55 elsewhere in the world (Chan-on *et al.*, 2013), with much higher levels of p53 mutation in
56 Thai CCA patients than European ones. It is therefore important to determine the effect of
57 heparin binding factor inhibition in CCA from patients with *O. viverrini* associated cancers.

58 Sulfated polysaccharides (SPs) are compounds found in extracts from various natural
59 sources such as terrestrial (Silva *et al.*, 2012), and marine plants (Vishchuk *et al.*, 2011),
60 mushrooms (Zhang *et al.*, 2012), and animals (Chen *et al.*, 2012). SPs have been shown to
61 regulate proliferation, migration, angiogenesis and differentiation in a variety of cells (Costa
62 *et al.*, 2010). SPs trigger signaling pathways involving in anti-proliferation and migration
63 (Wu *et al.*, 2006; Wu *et al.*, 2011). They have been shown to inhibit cancer cell proliferation
64 by induction of cell cycle arrest (Wong *et al.*, 2007) and by decreased growth factor secretion
65 in cancer cells (Cao & Lin, 2006).

66 Previous studies reported that SPs could either be stimulatory or inhibitory. For
67 instance, SPs extracted from an edible herbal plant, enhanced the binding of fibroblast growth
68 factor and its receptor, leading to the proliferation of neural stem/progenitor cells (Zhang *et al.*
69 *et al.*, 2010). In contrast, inhibitory effects of SPs on the binding of basic-fibroblast growth
70 factor and its co-receptor, leading to decreased proliferation of cancer cells (Xiong-Zhi *et al.*,
71 2011). SPs extracted from brown seaweed namely, fucoidan interrupted EGF-induced cell
72 transformation by blockage the EGF and EGFR interaction (Lee *et al.*, 2008). This suggests
73 that SPs could act either as activators or competitors in the recognition of growth factors by
74 their co-receptors, depending on cell type and SPs type.

75 Recently, sulfated galactans (SG) obtained from *Gracilaria fisheri* (*G. fisheri*), a red
76 seaweed cultivated in South East Asia, have been isolated (Wongprasert *et al.*, 2014). Several

77 biological activities have been reported including anti-viral (Rudtanatip *et al.*, 2014), anti-
78 coagulant (Pereira *et al.*, 2005), and immune stimulating activities (Rudtanatip *et al.*, 2015).
79 Various species of *Gracilaria* have been claimed to exhibit anti-malignant activity against
80 breast cancer and colon cancer (Zandi *et al.*, 2010). We previously demonstrated that the
81 structure of SG extracted from *G. fisheri* is a polysaccharide of galactose backbone and
82 contains a high percentage of sulfates (Wongprasert *et al.*, 2014), similar in structure to
83 HSPGs. Due to the structural similarity of SG and HSPGs, we hypothesized that SG could
84 imitate a co-receptor on the cell membrane and interact with growth factors or their receptors,
85 effecting an inhibitory effect on cancer cell activity. Therefore, this study aimed to evaluate
86 any anti-proliferation activity of SG in CCA cells lines, and determine any underlying anti-
87 proliferation mechanism of SG, especially through EGF-EGFR interaction

88

89 **Materials and Methods**

90 *Sulfated galactans (SG) from Gracilaria fisheri (G. fisheri)*

91 *G. fisheri* was collected from Suratthani Province, Thailand, washed, epiphytes removed, and
92 dried. Dried sample was extracted to obtain SG following the previously described protocol,
93 and the SG yielded was 3% of the seaweed dry weight (Wongprasert *et al.*, 2014). The
94 structure of SG analyzed by NMR and FT-IR consists of 3-linked- β -D-galactopyranose (G)
95 and 4-linked 3,6-anhydro- α -L-galactopyranose (LA) or α -L-galactose-6-sulfate (L6S) with
96 partial methylation (CH₃) at C-2 of LA and C-6 of G, and presence of sulfation on C-4 and C-
97 6 of D-galactopyranose units (G4S and G6S) (Fig. 1).

98

99 *Cell culture*

100 CCA cells (HuCCA-1, RMCCA-1 and KKU-M213) established from CCA tissue fragments
101 of Thai patients were tested for an anti-proliferation effect of SG. HuCCA-1 (Sirisinha *et al.*,
102 1991) and KKU-M213 are derived from a patient with intrahepatic bile duct CCA. RMCCA-

103 1 is derived from a patient with peripheral CCA (Rattanasinganchan *et al.*, 2006). They were
104 cultured at 37°C, 5% CO₂ in Ham F-12 nutrient mixture (Ham F-12) (Gibco Invitrogen,
105 USA) containing 1.17 g/L sodium bicarbonate (NaHCO₃), 5% FBS (Sigma Aldrich, USA)
106 and penicillin (100 units/mL) plus streptomycin (100 µg/mL) (Wiscent Inc. P.O., Canada).

107

108 *Direct binding of FITC-SG to HuCCA-1 cells by confocal laser scanning microscopy (CLSM)*
109 SG conjugated FITC was prepared as previously described (Rudtanatip *et al.*, 2015). Briefly,
110 one hundred milligrams of SG was dissolved in 1 mL of DMSO containing 15 µL of
111 pyridine. The SG mixture was mixed with powdered FITC (40 mg) and 2 mg/mL of dibutyltin
112 dilaurate, and then heated at 95 °C for 2 h. After precipitation with absolute ethanol overnight
113 at 4 °C, the mixture was centrifuged at 900×g for 15 min, and supernatant discarded. The
114 pellet was dissolved in 2-4 mL of PBS pH 7.4, the unbound FITC was removed with an
115 Amicon[®] Ultra Centrifugal Filter (Ultracel-30K) (Merck, Germany), centrifuged at 900×g,
116 for 5-10 min, and then the solution freeze-dried by Freeze Dry Supermodulyo-230 (Thermo
117 Scientific, USA).

118 HuCCA-1 cells were grown on poly-L-lysine-coated-coverslip in a 24-well plate
119 overnight at 37 °C. Cells were incubated with FITC without SG as a control or with FITC-
120 SG at 37 °C for 2 h in the dark, then washed thrice with PBS pH 7.4. The coverslips were
121 fixed with 4% paraformaldehyde in PBS for 10 min at RT. After washing in PBS, they were
122 mounted with mounting medium containing TO-PRO-3 (Sigma Aldrich, USA), and
123 examined under a Confocal Laser Scanning Microscope (FV10i-DOC) (Olympus, Japan).

124

125 *The SG-EGF binding using FAR-Western blot analysis*

126 The binding activity of SG with EGF protein was determined by Far-Western blot analysis as
127 previously described (Rudtanatip *et al.*, 2015). The recombinant EGF protein, lectin proteins
128 (positive controls) and 2% BSA (a negative control) were separated on 15% gel-SDS-PAGE,

129 stained with Coomassie blue, and blotted onto nitrocellulose membrane. The membrane was
130 incubated with 100 µg/mL of SG overnight at 4°C. After washing with 0.05% Tween-20 in
131 PBS (PBS-T), membrane was blocked with 10% non-fat dry milk in PBS-T for 2-4 h at room
132 temperature. The membrane was incubated with primary anti LM₅ monoclonal antibody
133 (Plant Probes, UK), which is specific to (1→4)-β-D-galactans of SG, overnight at 4°C,
134 followed by incubation with goat anti-rat HRP conjugated secondary antibody for 2 h at room
135 temperature. Complex of SG-proteins was visualized using the ECL kit and visualized on
136 Hyperfilm ECL.

137

138 *Co-immunoprecipitation for SG-EGFR binding*

139 Cell membrane protein was extracted in cold TE buffer (20 mM Tris-HCl, pH 7.5, 100 mM
140 NaCl, 1 mM EDTA, pH 8.0), homogenized with a hypodermic needle gauge size 26,
141 ultracentrifuged at 40,000×g, 4 °C for 10 min, the supernatant removed and pellet re-
142 suspended in cold TE buffer containing 2% Triton X-100 and protease inhibitor. After
143 ultracentrifugation at 100,000×g, 4 °C for 30 min, the supernatant was collected, and protein
144 concentration determined.

145 Pull down assay: The membrane protein lysate was incubated with SG (ratio 1:1),
146 shaking overnight at 4 °C. The Co-IP was performed using SureBeads™ Protein G magnetic
147 Beads (Bio-Rad, USA) following the manufacturer's protocol. Briefly, 100 µL of SureBeads
148 was washed with 0.1% Tween-20 in PBS pH 7.4 (PBS-T), magnetized and supernatant
149 discarded three times. The beads were then incubated with 100 µl of anti LM₅ monoclonal
150 antibody or IgG (Santa Cruz Biotechnology, USA) on a rotator for 10 min at room
151 temperature, magnetized, and supernatant discarded. The membrane protein lysate was
152 incubated with SG (ratio 1:1), shaken overnight at 4 °C, and then mixed with the beads,
153 rotated for 60 min at room temperature. After washing with PBS-T three times, 20 µL of
154 glycine (20 mM) pH 2.0 was added to the tube, incubated 5 min at room temperature,

155 magnetized, and then eluent containing immunocomplex protein collected. The eluent was
156 neutralized in 2 μ L of 1 M phosphate buffer (0.05 M dibasic sodium phosphate, 0.05 M
157 monobasic sodium phosphate), pH 7.4. The immunocomplex protein was separated on a 10%
158 polyacrylamide gel by SDS-PAGE, blotted onto nitrocellulose membrane (Merck Germany),
159 incubated with the primary anti EGFR antibody or IgG (Santa Cruz Biotechnology, USA)
160 then followed with HRP-conjugated secondary antibody. Immunoprecipitated proteins were
161 detected using the Enhanced Chemiluminescence (ECL) kit (GE Healthcare, UK) and
162 visualized on Hyperfilm ECL (Piscataway, USA). **The protein lysate without co-IP was also**
163 **immunoblotted with anti-EGFR antibody as a control. To confirm binding, EGFR in the cell**
164 **lysate was pulled down using Surebeads conjugated with anti-EGFR antibody or IgG, and the**
165 **eluent containing EGFR was separated on 10% SDS-PAGE gel and blotted onto**
166 **nitrocellulose membrane. The membrane was incubated with 100 μ g/mL of SG for overnight**
167 **at 4°C, immunoblotted with the anti LM₅ monoclonal antibody or IgG, incubated with the**
168 **HRP-conjugated secondary antibody, detected using ECL kit, and visualized on Hyperfilm**
169 **ECL.**

170

171 *MTT assay*

172 CCA cells (HuCCA-1, RMCCA-1 and KKV-M213) were grown overnight in a 96-well plate
173 at density 1×10^4 cells/well. Cells were incubated with different concentrations of SG (0, 10,
174 20, 50 and 100 μ g/mL) for 48 h. After incubation cell proliferation was determined using
175 methyl thiazolium bromide (MTT) assay. Briefly, 100 μ L of MTT solution (0.5 mg/mL)
176 (Sigma Aldrich, USA) was added to each well and incubated for 4 h at 37°C in the dark.
177 After incubation, 100 μ L of dimethyl sulfoxide (DMSO) (Merck, Germany) was added to
178 each well, and the absorbance of the sample was measured at OD 490 nm by a Versamax
179 microplate reader using SoftMax[®] Pro 4.8 analysis software (Molecular Devices, USA).

180 To determine an ability of SG to inhibit epidermal growth factor (EGF) induced CCA
181 cell growth, HuCCA-1 cells were treated with SG (10 and 50 µg/mL) or EGF (5 ng/mL)
182 (Cell signaling Technology, USA) or both SG and EGF. After incubation for 48 h, cell
183 proliferation was determined by MTT assay.

184

185 *Cell cycle analysis using flow cytometry*

186 HuCCA-1 cells were starved with free fetal bovine serum (FBS) overnight to synchronize
187 cells to quiescent stage. Cells were incubated with or without SG (10, 50 µg/mL) for 24 h,
188 then collected, washed twice with phosphate buffer saline (PBS), pH 7.4 and centrifuged.
189 Cells were suspended in 70% cold ethanol in PBS pH 7.4 at -20° C for 30 min, washed twice
190 in 1 mL of PBS, and then 5 µL of 10 mg/mL of RNase (Roche Diagnostics, USA) was added.
191 After incubation at 37° C for 30 min, cells were stained in 100 µL of 0.5 mg/mL propidium
192 iodide (PI) (Sigma Aldrich, USA) at 4°C in the dark for 10 min. DNA content of cells was
193 determined using BD FACSCanto™ flow cytometer (BD Biosciences, USA).

194

195 *Reverse transcription PCR of cyclin-D, cyclin-E, cdk-4 and cdk-2*

196 **The key regulators driving cells from G₀/G₁ phase to S phase include cyclin-D, cyclin-E, cdk-**
197 **4, and cdk-2. Therefore, we determined the mRNA expression of these genes.** After 24 h
198 incubation, cells were collected and washed twice with PBS. Total RNA was extracted using
199 Trizol reagent as manufacturer's instruction (Molecular research Center, Inc, USA). The
200 concentration and purity of RNA were determined using a Nano drop-2000C
201 spectrophotometer (Thermo Scientific, USA). Total RNA (1 µg) was reverse-transcribed to
202 cDNA in a total volume of 20µl system by using the Revert Aid First Strand cDNA Synthesis
203 Kit (Thermo Scientific, USA) following the manufacturer's protocol. The PCR product was
204 obtained by using Thermo Scientific Phusion High-Fidelity DNA polymerase (Thermo
205 Scientific, USA) following the manufacturer's protocol. The PCR conditions were as follows:

206 1 cycle of initial denaturation at 98 °C for 30 sec, 27-35 cycles of denaturation at 98 °C for
207 10 sec, annealing temperature and number of cycles for each particular genes, extension at 72
208 °C for 30 sec, and final extension 1 cycle at 72 °C for 5 min. The specific PCR primer
209 sequences and amplification conditions of cyclin-D, cyclin-E, cdk-4 and cdk-2 are shown in
210 Table 1. The PCR products were separated on 1.5% W/V agarose gel, tris-borate-
211 ethylenediaminetetraacetic acid (TBE)-buffered, containing 0.5 µg/mL of ethidium bromide.
212 The PCR bands were visualized using UVP EpiChem III *Darkroom* (UVP Bioimaging
213 Systems, USA). Expression of cyclin-D, cyclin-E, cdk-4 and cdk-2 were quantified by
214 ImageJ analysis program (from NIH website by Scion Corporation, Frederick, MD).

215

216 *Western blot analysis*

217 The cyclin/cdk complexes are negatively regulated by cdk inhibitor, P21; and transcription of
218 P21 is induced by a tumor suppressor protein P53. EGFR activation by its ligands EGF leads
219 to EGFR phosphorylation, thereby stimulating downstream signaling cascades using the
220 MAPK/ERK pathway involved in cell proliferation. We, therefore, determined the protein
221 expression levels of the key regulators, P21, P53, p-EGFR and p-ERK by Western blotting.
222 HuCCA-1 cells were incubated with or without SG (10, 50 µg/mL) for 24 h. Cells were
223 collected and whole cell lysates were prepared in lysis buffer (3 mM MgCl₂, 1 mM EGTA, 10
224 mM sodium pyrophosphate (NaPpi), 10 mM sodium orthovanadate (Na₃VO₄), 50 mM
225 sodium fluoride (NaF) and 100 X protease inhibitor solution) and centrifuged at 8,500×g for
226 15 min at 4°C. The supernatant was collected to determine protein concentration by BCA
227 assay using the Pierce™ BCA Protein Assay Kit (Thermo Scientific, USA). Proteins were
228 separated on 10-12.5% gel SDS-PAGE, blotted onto a nitrocellulose membrane (Merck,
229 Germany), and incubated with primary antibodies:- cyclin-D, cyclin-E, P53, P21, EGFR, p-
230 EGFR, and p-ERK antibodies (Santa Cruz Biotechnology, USA), followed by incubation
231 with horseradish-peroxidase-conjugated (HRP) secondary antibody. Anti-alpha (α)-tubulin

232 antibody (Santa Cruz Biotechnology, USA) was also probed in all blots as an internal control.
233 Proteins were detected using the Enhanced Chemiluminescence (ECL) kit (GE Healthcare,
234 UK) and visualized on Hyperfilm ECL (Piscataway, USA). Expression of protein was
235 quantified by ImageJ analysis program (from NIH website by Scion Corporation, Frederick,
236 MD).

237 To determine whether SG could decrease EGF induced EGFR activation, cells were
238 treated with SG (10, 50 $\mu\text{g}/\text{mL}$) with or without EGF (5 ng/mL) or with only EGF for 24 h at
239 37 °C. **In addition, to determine whether SG mediated inhibiting effects through EGFR, cells**
240 **were pretreated with the anti EGFR antibody (Sigma Aldrich, USA) to neutralize EGFR for 2**
241 **h prior exposure to SG or EGF for 24 h.** After incubation, cells were collected for protein
242 extraction and expression of p-EGFR determined.

243

244 *Statistical analysis*

245 All methods were performed in three independent experiments. Data are presented as means
246 \pm SEM and statistically analyzed by one-way ANOVA followed by Turkey's multiple
247 comparison tests using GraphPad Prism program version 6 (GraphPad software, USA).
248 Difference with *p*-values less than 0.05 were considered statistically significant.

249

250 **Results**

251 *The interaction of SG with HuCCA-1 cells*

252 The binding activity of SG to HuCCA-1 cells was determined by immunofluorescence and
253 Co-IP experiments. The CLSM micrographs revealed that FITC conjugated SG could bind to
254 HuCCA-1 cells whereas FITC by itself showed no binding activity (Fig. 2A). SG interaction
255 with EGFR was examined by Co-IP experiments. SG was allowed to bind with HuCCA-1
256 cell membrane protein lysate and the SG-protein complex was pulled down using anti LM₅
257 antibody (a specific antibody against SG). **The result demonstrated that SG-protein complex**

258 showed a positive immunoblot with anti-EGFR antibody. In the converse experiment, cell
259 lysate immunoprecipitated with anti EGFR antibody, incubated with SG, and followed with
260 immunoblotting with the anti-LM₅ antibody also showed an immunoreactive band at the same
261 size (Fig. 2B). The cell membrane lysate without co-IP (a positive control) probed with anti-
262 EGFR antibody showed a positive EGFR band, while the cell membrane lysate from co-IP
263 probed with IgG of the same species of the antibodies revealed a negative immunoblot. These
264 results suggested that SG could interact with EGFR. Moreover, an ability of SG to bind with
265 EGF was evaluated by Far-Western blot analysis. The result revealed that SG could interact
266 to controls including commercial lectin, RCA and WGA, but could not interact with the
267 recombinant EGF tested (Fig. 2C).

268

269 *SG inhibited CCA cell proliferation and EGFR activation*

270 Various CCA cell lines included HuCCA-1, RMCCA-1 and KKV-M213 cells were used to
271 test the anti-proliferation effect of SG. The results revealed that SG at different
272 concentrations (0, 10, 20, 50 and 100 µg/mL) significantly decreased proliferation in all
273 tested CCA cell lines (Fig. 3 A-C). Proliferation, migration/invasion and angiogenesis
274 activities in various cancer cells are mediated through activation of EGFR signaling pathway.
275 We therefore investigated the EGFR-MAPKs/ERK signaling pathway, a major downstream
276 signaling cascade of EGFR activation. **The results demonstrated that cells treated with SG**
277 **showed levels of EGFR expression not different from control but decreased level of p-EGFR**
278 **(Fig. 4A) and p-ERK (Fig. 4B).**

279

280 *SG suppressed EGF induced EGFR activation*

281 We further determined whether SG could inhibit EGF induced HuCCA-1 cell proliferation.
282 To test this, cells were pretreated with or without SG (10 and 50 µg/mL) before stimulating
283 with EGF (5 ng/mL). The results showed that treatment of cells with SG alone at

284 concentrations of 10 and 50 $\mu\text{g}/\text{mL}$ decreased cell number to 78 ± 2.4 and $75 \pm 6.4\%$ of
285 control, respectively. Treatment of cells with EGF alone increased cell number to $128 \pm 6.4\%$
286 of control. Treatment of cells with SG before stimulation with EGF decreased cell number to
287 94 ± 2.7 and $88 \pm 1.2\%$ of control, respectively, significantly less than cells treated with EGF
288 alone (Fig. 5A). Cells treated with SG alone or with SG prior exposure to EGF decreased
289 levels of p-EGFR expression from control. Both showed that phosphorylation of EGFR was
290 less than in cells treated with EGF alone (Fig. 5B). **Moreover, when EGFR was neutralized**
291 **with anti EGFR antibody prior SG treatment, cells restored the level of p-EGFR to that of**
292 **control (Fig. 6). Collectively, the results suggested that SG might interact with EGFR and**
293 **mediate inhibition of cell proliferation, in part, by preventing endogenous activation of the**
294 **EGFR-MAPK/ERK pathway.**

295

296 *SG inhibited CCA cells proliferation by arresting cells at G_0/G_1 phase*

297 To investigate the effect of SG on cell cycle, HuCCA-1 cells were treated with SG (10 and 50
298 $\mu\text{g}/\text{mL}$) and cell populations determined. Flow cytometry showed that cells treated with SG
299 significantly increased the percentage of cells in G_0/G_1 phase and decreased those in S phase
300 compared with controls (Fig. 7). The results suggested that SG retarded the cells at G_0/G_1
301 phase.

302 **We further determined expressions of the key regulators in the G_0/G_1 phase transition**
303 **and tumor suppressor proteins that control cell cycle in HuCCA-1 cells.** RT-PCR analysis
304 showed that cells treated with SG induced a dose dependent decrease in mRNA transcripts of
305 cyclin-D, cyclin-E, cdk-4 and cdk-2 (Fig. 8). Western blot analysis showed that cells treated
306 with SG decreased protein levels of cyclin-D, cyclin-E (Fig. 9A, B), and concurrently
307 increased expression levels of the tumor suppressor protein P53 and cyclin-dependent kinase
308 inhibitor P21 compared with control (Fig. 9C, D). These results indicated that SG induced

309 HuCCA-1 cells arrested at G₀/G₁ phase by downregulating cyclin-D, cyclin-E, cdk-4 and
310 cdk-2 and upregulating P53 and P21.

311

312 **Discussion and Conclusion**

313 Cholangiocarcinoma (CCA) is a malignant biliary epithelial cell transformation, which has
314 very poor prognosis due to its resistance to radiotherapy and chemotherapy (Zografos *et al.*,
315 2011). CCA is more common in North East Thailand than anywhere else in the world due to
316 endemic *O. viverrini* infection. Critically, while most trials of anti-cancer drugs have been
317 tried in western cholangiocarcinoma, CCA from Thailand are genetically distinct, and have
318 different activated signal transduction pathways. Therefore it is critical to understand the
319 biology of CCA derived from patients with *O. viverrini* associated carcinoma. It is well
320 established that growth factors and their receptor activation are important signals in
321 regulating cancer cell bioactivities. Many growth factor receptors require HSPGs as a co-
322 receptor to bind and activate them (Afratis *et al.*, 2012). EGFR is a member of the ErbB
323 family of receptor tyrosine kinases, and plays a critical role in development and cancer cell
324 progression. Dimerization and phosphorylation of EGFR by EGF activates a series of
325 intracellular signaling cascades to affect transcription of genes regulating cancer cell
326 proliferation, reduced apoptosis, invasion and metastasis and also stimulates tumor-induced
327 angiogenesis (Hynes & MacDonald, 2009). Previous studies have shown that EGFR is
328 overexpressed in CCA human samples (Harder *et al.*, 2009). EGFR activation triggers the
329 MAPK-ERK signaling pathway in cholangiocytes (Yoon *et al.*, 2004).

330 It has been reported that natural SPs have structures similar to HSPGs and imitate the
331 function of HSPGs. They can act to block the binding of growth factor/receptor and co-
332 receptor, resulting in suppression the activation of receptor downstream signaling pathway in
333 cancer cells (Lee *et al.*, 2008; Cheng *et al.*, 2012). Recently, we have isolated SPs –
334 specifically SG - from red seaweed *Gracilaria fisheri* (*G. fisheri*) with structure similar to

335 heparan sulfate (Wongprasert *et al.*, 2014). SG might compete for binding with the growth
336 factor/receptor or co-receptor due to its structural similarity to HSPGs. Therefore, we have a
337 hypothesis that SG might interact with EGFR or EGF, thereby preventing EGFR activation,
338 and thus decreasing CCA cells proliferation. In the present study, we show that SG could
339 bind to HuCCA-1 cells. **Additionally, far western blotting and Co-IP assay revealed that SG**
340 **did not interact directly with EGF but interacted with EGFR.** SG demonstrated the anti-
341 proliferation effects against three different CCA cell lines derived from Thai patients,
342 (HuCCA-1, RMCCA-1 and KKU-M213). **We investigated the effects of SG on EGFR**
343 **signaling cascades regulating proliferation in HuccA-1 cells. Our results reveal that SG has**
344 **no effect on EGFR expression but down-regulated phosphorylation of EGFR and ERK in**
345 **HuCCA-1 cells. Moreover, it inhibited EGF-induced proliferation. Additionally, when EGFR**
346 **was neutralized, (reducing pEGFR on the cell membrane) and followed by SG treatment,**
347 **cells restored the levels of p-EGFR to normal. These results suggest that SG could not**
348 **downregulate EGFR but required interaction with EGFR to reduce EGFR activation.** This
349 competitive binding of SG might interfere with receptor dimerization thus decreasing the
350 level of p-EGFR and p-ERK, the signaling molecules in EGFR/MAPK/ERK pathway
351 controlling cell cycle. The specific binding site of SG on EGFR and the underlined scenario
352 by which SG mediated suppress EGFR activation need further investigation.

353 SG exhibited anti-cancer activity against Thai cholangiocarcinoma by modulating cell
354 cycle regulators and inhibiting ERK expression. This is consistent with findings from other
355 groups on other SPs (Zhang *et al.*, 2012; Park *et al.*, 2015). SG inhibited HuCCA-1 cells
356 proliferation by arresting cells at G₀/G₁ phase, with no apoptosis (no sub-G₁ peak in cell
357 cycle). This is in contrast with a previous study, which reported that fucoidans, SPs from
358 brown seaweed, induced apoptosis and inhibited cell viability of bladder cancer cells, T24
359 (Park *et al.*, 2014). At G₀/G₁ phase, the main cell-cycle regulators are cyclin/cdk complexes
360 (cyclin-D/cdk-4, cdk-6, cyclin-E/cdk-2) for transition to S-phase. These regulators are

361 negatively regulated by cdk inhibitors (CDKI), P21 (Dobashi *et al.*, 2003) which are
362 important for abnormal or cancer cells being able to evade the G₁ restriction point, and
363 continue to proliferate in S, G₂ and M phases (Fuster & Esko, 2005). P21 binds to and
364 inhibits the kinase activity of CDKs leading to growth arrest at specific stages in the cell
365 (Sherr & Roberts, 1999). Indeed, transcription of p21 can be induced by a tumor suppressor
366 protein P53, and thus it acts as an indirect effector of tumor suppressor pathways for
367 promoting cell cycle arrest (Benson *et al.*, 2014). Previous studies in Thai CCA cell lines
368 have shown that CCA cell treatment with chemotherapeutic agents such as doxorubicin and
369 gemcitabine up-regulated P53 and P21 expression (Zeekpudsa *et al.*, 2014), and dicoumarol
370 at non-cytotoxic concentrations enhanced the level of P53 protein (Buranrat *et al.*, 2010),
371 expression of which was associated with the strong anti-proliferative effect. p53 is the most
372 commonly mutated tumor suppressor gene associated with the development of human cancer
373 and has been implicated in cholangiocarcinoma development by various studies. It is noted
374 that the Thai CCA cell lines and CCA tissues expressed both wild type and mutant p53
375 (Nutthasirikul *et al.*, 2013). Mutant p53 was non-functional, while wild type p53 mediated
376 p53 transcriptional activation. Our results showed that increased expression of P21 was
377 associated with P53 proteins suggesting that SG might induce P21 up-regulation via
378 activation of wild type p53 transcription, and the inhibiting effect of SG on CCA cell
379 proliferation can occur in cells expressing mutant p53. However, this study could not
380 identify specific P53 isoforms due to the limitation of the P53 antibody in Western blot
381 analysis. Collectively, the results suggest that SG reduced proliferation of HuCCA-1 cells by
382 arresting the cells at G₁ phase through the down-regulation of cyclin-D, cyclin-E, cdk-4 and
383 cdk-2, and also by induction of P53 and P21.

384 The Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein
385 (MAP) kinase signaling pathway is among the key mechanisms that transmit signals upon
386 receptor activation from the cell surface to the nucleus, eliciting proliferative and survival

387 signals in cancer cells. In particular, its role in cell cycle progression in G₁ phase and cell
388 proliferation is well established. Growth factors induce phosphorylation and activation of
389 ERK, which subsequently is translocated from the cytoplasm to the nucleus, where p-ERK
390 activates several nuclear ERK targets (Sun *et al.*, 2015). Here we show that SG decreased
391 HuCCA-1 cell proliferation by inhibiting cell cycle progression was correlated with
392 decreased expression of p-EGFR and p-ERK. Our results are consistent with a previous study
393 in mouse epidermal JB6C141 cells that marine SPs from *Laminaria guryanovae* decreased
394 expression of p-EGFR (Lee *et al.*, 2008). The previous reports demonstrated that ERK
395 activation is required for induction of cyclin-D up-regulation and reduction of P53 and P21
396 for driving cells from G₀/G₁ to S phase (Massagué, 2004). Our study suggests that SG might
397 inhibit ERK activation leading to the reduction of cyclin-D, along with the induction of the
398 cdk inhibitor P21 to stabilize cyclin-D/cdk4 complexes, thus cells fail to enter S-phase.

399 Taken together, this study demonstrates the anti-proliferation effect of SG from *G.*
400 *fisheri* against HuCCA-1 cells is by arresting the cell at G₁ phase, and its inhibition
401 mechanism is mediated, to a lesser extent, through EGFR and EGFR/MAPK/ERK signaling.
402 SG presents a potential EGFR targeted molecule, which may be further clinically developed
403 as an adjuvant for enhancing the efficacy of chemotherapeutic agents for CCA treatment.
404 Moreover, the SG demonstrates a potential to overcome drug resistance in CCA with mutated
405 p53 treatment.

406

407 **Acknowledgements**

408 This work is supported by the Medical Research Council (MRC) through UK-
409 Thailand Research Collaborations (Newton Fund) (MR/N01247X/1), the Thailand Research
410 Fund (DBG 5980006), and the Royal Golden Jubilee Ph.D. Program (PHD/0305/2551).

411

412 **References**

- 413 Afratis, N., C. Gialeli, D. Nikitovic and T. Tsegenidis. Glycosaminoglycans: Key players in
414 cancer cell biology and treatment. *Eur. J. Biochem.* 279: 1177-1197, 2012.
- 415 Benavides, M., A. La Casta, B. Laquente, T. Macarulla, J.R.Rodríguez-Mowbray and J.
416 Maurel. Biliary tract cancers: SEOM clinical guidelines. *Clin. Transl. Oncol.* 17: 982-
417 987, 2015.
- 418 Benson, E.K., S.K. Mungamuri, O. Attie, M. Kracikova, R. Sachidanandam, J.J. Manfredi,
419 and S.A. Aaronson. p53-dependent gene repression through p21 is mediated by
420 recruitment of E2F4 repression complexes. *Oncogene.* 33: 3959-3969, 2014.
- 421 Buranrat, B., A. Prawan, U. Kukongviriyapan, S. Kongpetch and V. Kukongviriyapan.
422 Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing
423 cholangiocarcinoma cells. *World J. Gastroenterol.* 16: 2362-2370, 2010.
- 424 Cao, Q. Z. and Z.B. Lin. *Ganoderma lucidum* polysaccharides peptide inhibits the growth of
425 vascular endothelial cell and the induction of VEGF in human lung cancer cell. *Life Sci.*
426 78: 1457-1463, 2006.
- 427 Chan-on, W., M.L. Nairismagi, C.K. Ong and W.K. Lim. Exome sequencing identifies
428 distinct mutational patterns in liver fluke-related and non-infection-related bile duct
429 cancers. *Nat. Genet.* 45: 1474-1478, 2013.
- 430 Chen, D., X. Zhang, Y. Du and Z. Wen. Effects of gekko sulfated polysaccharide–protein
431 complex on the defective biorheological characters of dendritic cells under tumor
432 microenvironment. *Cell Biochem. Biophys.* 62:193-201, 2012.
- 433 Cheng, J. J., C.C. Chang, C.H. Chao and M.K. Lu. Characterization of fungal sulfated
434 polysaccharides and their synergistic anticancer effects with doxorubicin. *Carbohydr*
435 *Polym.* 90: 134-139, 2012.
- 436 Clapéron, A., M. Mergey, T.H. Nguyen Ho-Boulidoires, D. Vignjevic, N. Guedj and L.
437 Fouassier. EGF/EGFR axis contributes to the progression of cholangiocarcinoma
438 through the induction of an epithelial-mesenchymal transition. *J. Hepatol.* 61: 325-332,
439 2014.
- 440 Costa, L.S., G.P. Fidelis, S.L. Cordeiro and R.M. Oliveira. Biological activities of sulfated
441 polysaccharides from tropical seaweeds. *Biomed. Pharmacother.* 64: 21-28, 2010.
- 442 Dobashi, Y., T. Takehana and A. Ooi. Perspectives on Cancer Therapy: Cell Cycle Blockers
443 and Perturbators. *Curr. Med. Chem.* 10: 2549-2558, 2003.
- 444 Fuster, M. M. and J.D. Esko. The sweet and sour of cancer: glycans as novel therapeutic
445 targets. *Nat. Rev. Cancer.* 5: 526-542, 2005.

- 446 Harder, J., O. Waiz, F. Otto, M. Geissler, M. Olschewski, B. Weinhold and O.G. Opitz.
447 EGFR and HER2 expression in advanced biliary tract cancer. *World J. Gastroenterol.*
448 15: 4511-4517, 2009.
- 449 Hoffmann, A.C., E. Goekkurt, P.V. Danenberg, S. Lehmann, G. Ehninger, D.E. Aust and J.
450 Stoehlmacher-Williams. EGFR, FLT1 and Heparanase as Markers Identifying Patients
451 at Risk of Short Survival in Cholangiocarcinoma. *PLoS ONE*. 8: e64186, 2013.
- 452 Hynes, N.E. and G. MacDonald. ErbB receptors and signaling pathways in cancer. *Curr.*
453 *Opin. Cell Biol.* 21: 177-184, 2009.
- 454 Iwamoto, R., N. Mine, T. Kawaguchi, S. Minami, K. Saeki and E. Mekada. HB-EGF
455 function in cardiac valve development requires interaction with heparan sulfate
456 proteoglycans. *Development*. 137: 2205-2214, 2010.
- 457 Kessler, E.R., S.G. Eckhardt, T.M. Pitts, E.L. Bradshaw-Pierce, E. Freas and S. Leong. Phase
458 I trial of vandetanib in combination with gemcitabine and capecitabine in patients with
459 advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
460 *Invest. New Drug*. 34: 176-183, 2016.
- 461 Khan, S.A., H.C. Thomas, B.R. Davidson and S.D. Taylor-Robinson. Cholangiocarcinoma.
462 *The Lancet*. 366: 1303-1314, 2005.
- 463 Lee, N. Y., S.P. Ermakova, T.N. Zvyagintseva and K.W. Kang. Inhibitory effects of fucoidan
464 on activation of epidermal growth factor receptor and cell transformation in JB6 Cl41
465 cells. *Food Chem. Toxicol.* 46:1793-1800, 2008.
- 466 Massagué, J. G₁ cell-cycle control and cancer. *Nature*. 432: 298-306, 2004.
- 467 Nutthasirikul, N., T. Limpai boon, C. Leelayuwat, S. Patrakitkomjorn and P. Jearanaikoon.
468 Ratio disruption of the 133p53 and TAp53 isoform equilibrium correlates with poor
469 clinical outcome in intrahepatic cholangiocarcinoma. *Int. J. Oncol.* 42: 1181-1188,
470 2013.
- 471 Park, H.Y., W. Choi, G.Y. Kim, W. J. Kim and Y.H. Choi. Fucoidan induces G1 arrest of the
472 cell cycle in EJ human bladder cancer cells through down-regulation of pRB
473 phosphorylation. *Rev. bras. farmacogn.* 25: 246-251, 2015.
- 474 Park, H. Y., G.Y. Kim, S.K. Moon, W.J. Kim, Y.H. Yoo and Y.H. Choi. Fucoidan inhibits
475 the proliferation of human urinary bladder cancer T24 cells by blocking cell cycle
476 progression and inducing apoptosis. *Molecules*. 19: 5981-5998, 2014.
- 477 Pereira, M. G., N.M.B. Benevides and M.R.S. Melo. Structure and anticoagulant activity of a
478 sulfated galactan from the red alga, *Gelidium crinale*. Is there a specific structural
479 requirement for the anticoagulant action?. *Carbohydr. Res.* 340: 2015-2023, 2005.

- 480 Rattanasinganchan, P., K. Leelawat, S.A. Treepongkaruna, C. Tocharoentanaphol, S.
481 Subwongcharoen, T. Suthiphongchai. R. Tohtong. Establishment and characterization
482 of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. *World J.*
483 *Gastroenterol.* 12: 6500-6506, 2006.
- 484 Rudtanatip, T., S. Asuvapongpatana, B. Withyachumnarnkul and K. Wongprasert. Sulfated
485 galactans isolated from the red seaweed *Gracilaria fisheri* target the envelope proteins
486 of white spot syndrome virus and protect against viral infection in shrimp haemocytes.
487 *J. Gen. Virol.* 95: 1126-1134, 2014.
- 488 Rudtanatip, T., B. Withyachumnarnkul and K. Wongprasert. Sulfated galactans from
489 *Gracilaria fisheri* bind to shrimp haemocyte membrane proteins and stimulate the
490 expression of immune genes. *Fish Shellfish Immunol.* 47: 231-238, 2015.
- 491 Sherr, C. and J. Roberts. CDK inhibitors: positive and negative regulators of G₁-phase
492 progression. *Genes Dev.* 13: 1501, 1999.
- 493 Silva, D. C., A.L.P. Freitas, F.C.N. Barros and K. O. A. L. Lins. Polysaccharide isolated from
494 *Passiflora edulis*: Characterization and antitumor properties. *Carbohydr Polym.* 87:
495 139-145, 2012.
- 496 Sirisinha, S., T. Tengchaisri, S. Boonpucknavig, N. Prempracha, S. Ratanarapee and A.
497 Pausawasdi. Establishment and Characterization of a Cholangiocarcinoma Cell Line
498 from a Thai Patient with Intrahepatic Bile Duct Cancer. *Asian Pac. J. Allergy Immunol.*
499 9: 153, 1991.
- 500 Sriamporn, S., P. Pisani, V. Pipitgool, K. Suwanrungruang, S. Kamsa-ard and D.M. Parkin.
501 Prevalence of *Opisthorchis viverrini* infection and incidence of cholangiocarcinoma in
502 Khon Kaen, Northeast Thailand. *Trop. Med. Int. Health*, 9: 588-594, 2004.
- 503 Sripa, B., J.M. Bethony, P. Sithithaworn, S. Kaewkes and E. Mairiang. *Opisthorchiasis* and
504 *Opisthorchis*-associated cholangiocarcinoma in Thailand and Laos. *Acta Trop.* 120:
505 S158-S168, 2011.
- 506 Sun, Y., W.Z. Liu, T. Liu, X. Feng, N. Yang, H.F. Zhou. Signaling pathway of MAPK/ERK
507 in cell proliferation, differentiation, migration, senescence and apoptosis. *J. Recept.*
508 *Signal Transduct. Res.* 35: 600-604, 2015.
- 509 Tushar, P. Worldwide trends in mortality from biliary tract malignancies. *BMC Cancer*, 2:
510 10, 2002.
- 511 Vishchuk, O. S., S.P. Ermakova and T.N. Zvyagintseva. Sulfated polysaccharides from
512 brown seaweeds *Saccharina japonica* and *Undaria pinnatifida*: isolation, structural
513 characteristics, and antitumor activity. *Carbohydr. Res.* 346: 2769-2776, 2011.

- 514 Wong, S. M., K.K. Wong, L.C.M Chiu and P.C.K. Cheung. Non-starch polysaccharides from
515 different developmental stages of *Pleurotus tuber-regium* inhibited the growth of
516 human acute promyelocytic leukemia HL-60 cells by cell-cycle arrest and/or apoptotic
517 induction. *Carbohydr. Polym.* 68: 206-217, 2007.
- 518 Wongprasert, K., T. Rudtanatip and J. Praiboon. Immunostimulatory activity of sulfated
519 galactans isolated from the red seaweed *Gracilaria fisheri* and development of
520 resistance against white spot syndrome virus (WSSV) in shrimp. *Fish Shellfish*
521 *Immunol.* 36: 52-60, 2014.
- 522 Wu, X., D. Chen and G.R. Xie. Effects of Gekko sulfated polysaccharide on the proliferation
523 and differentiation of hepatic cancer cell line. *Cell Biol. Int.* 30: 659-664, 2006.
- 524 Wu, X. Z., D. Chen and X.Q. Han. Anti-migration effects of Gekko sulfated glycopeptide on
525 human hepatoma SMMC-7721 cells. *Molecules.* 16: 4958-4970, 2011.
- 526 Xiong-Zhi, W., Z. Shuang-Xia, Z. Cong and C. Dan. Effects of sulfated polysaccharide
527 extracted from *Prunella vulgaris* on endothelial cells. *J. Med. Plants Res.* 5: 4218-
528 4223, 2011.
- 529 Yoon, J. H., G.Y. Gwak, H.S. Lee, S.F. Bronk, N.W. Werneburg and G.J. Gores. Enhanced
530 epidermal growth factor receptor activation in human cholangiocarcinoma cells. *J.*
531 *Hepatol.* 41: 808-814, 2004.
- 532 Yoshikawa, D., H. Ojima, M. Iwasaki, N. Hiraoka and T. Shibata. Clinicopathological and
533 prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
534 *Br. J. Cancer.* 98:418-425, 2007.
- 535 Yoshikawa, D., H. Ojima, A. Kokubu, T. Ochiya, S. Kasai, S. Hirohashi and T. Shibata.
536 Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel
537 molecular-targeted therapy against cholangiocarcinoma. *Br. J. Cancer,* 100: 1257-
538 1266, 2009.
- 539 Zandi, K., S. Tajbakhsh, I. Nabipour, Z. Rastian, F. Yousefi, S. Sharafian and K. Sartavi. In
540 vitro antitumor activity of *Gracilaria corticata* (a red alga) against Jurkat and molt-4
541 human cancer cell lines. *Afr. J. Biotechnol.* 9: 6787 - 6790, 2010.
- 542 Zeekpudsa, P., V. Kukongviriyapan, L. Senggunprai, B. Sripa, B. and A. Prawan.
543 Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of
544 cholangiocarcinoma cells to chemotherapeutic agents. *J. Exp. Clin. Cancer Res.* 33:
545 11-23, 2014.
- 546 Zhang, J., Y.J. Liu, H.S. Park, Y.M. Xia and G.S. Kim. Antitumor activity of sulfated
547 extracellular polysaccharides of *Ganoderma lucidum* from the submerged fermentation
548 broth. *Carbohydr. Polym.* 87: 1539-1544, 2012.

549 Zhang, Y., S. Song, D. Song, H. Liang, W. Wang, and A. Ji. Proliferative effects on neural
550 stem/progenitor cells of a sulfated polysaccharide purified from the sea cucumber
551 *Stichopus japonicus*. *J. Biosci. Bioeng.* 109: 67-72, 2010.

552 Zografos, N.G., A. Farfaras, F. Zagouri, D. Chrysikos and K. Karaliotas.
553 Cholangiocarcinoma: principles and current trends. *HBPD Int.* 10: 10-20, 2011.

554

555 **Legends**

556 **Fig. 1** The structural feature of sulfated galactans (SG) from *G. fisheri*. SG is a partially
557 pyruvated and methylated agarose structure, which consists of 3-linked- β -d-galactopyranose
558 (G) and 4-linked 3,6-anhydro- α -L-galactopyranose (LA) or α -l-galactose-6-sulfate (L6S)
559 with partial methylation (CH_3) at C-2 of LA and C-6 of G, and presence of sulfation on C-4
560 and C-6 of d-galactopyranose units (G4S and G6S) (Wongprasert *et al.*, 2014).

561

562 **Fig. 2** Representative data of SG interaction with CCA cells. (A) Confocal laser scanning
563 micrographs showed the adherence of FITC-SG to HuCCA-1 cells in X-Y and X-Z axis
564 whereas control cells incubated with FITC only showed no green fluorescence. FITC-SG is
565 represented in green color and nuclei stained with TO-PRO-3 represent in red color. Scale
566 bars = 150 μm . (B) Left: cell membrane lysate was allowed to bind with SG, and proteins
567 bound with SG were pulled down using anti-LM5 antibody. The eluent was then
568 immunoblotted with anti-EGFR antibody. Middle: Cell membrane lysate without co-IP was
569 blotted with anti-EGFR antibody as an EGFR blotted control. Right: in the converse
570 experiment, cell membrane lysate was pulled down with anti-EGFR antibody, and then the
571 eluent was incubated with SG before immunoblotted with anti-LM₅ antibody. The results
572 revealed the interaction of SG with EGFR. The lysate was also probed with IgG of the same
573 species of the antibodies raised, and the results were negative. (C) Right: SDS-PAGE gels
574 showing coomassie-brilliant blue staining of lectins (RCA, WGA) as positive controls,
575 recombinant EGF and BSA (negative control). Left: Far-Western blotting showing SG
576 bound to lectins (RCA and WGA), but not BSA and the recombinant EGF.

577

578 **Fig. 3** The effect of SG on CCA cell proliferation. (A) HuCCA-1, (B) RMCCA-1 and (C)
579 KKU-M213 were treated with different concentrations of SG (0, 10, 20, 50 and 100 $\mu\text{g}/\text{mL}$)
580 for 48 h. Cell viability was measured using MTT assay. Results are presented as a mean \pm
581 SEM of triplets independent experiments; $*p < 0.05$ compared to control.

582

583 **Fig. 4** Western blot analysis showing the relative expressions of (A) **EGFR and p-EGFR** and
584 (B) p-ERK to α -tubulin protein in HuCCA-1 cells after treatment with SG for 24 h. Results
585 are presented as a mean \pm SEM of triplets independent experiments; $*p < 0.05$ compared to
586 the respective control.

587

588 **Fig. 5** SG inhibited EGF induced HuCCA-1 cells proliferation and EGFR activation. (A) Cell
589 viability of HuCCA-1 cells measured by MTT assay. HuCCA-1 cells were pretreated with
590 SG (10 and 50 $\mu\text{g}/\text{mL}$) followed with or without EGF (5 ng/mL) for 24 h. (B) Western blot
591 analysis of p-EGFR in HuCCA-1 cells and relative expression of p-EGFR to α -tubulin in
592 different treatment groups. Cells were pre-treated with or without SG and then post-treated
593 with or without EGF for 24 h. Results are presented as a mean \pm SEM of three independent
594 experiments; $*p < 0.05$ compared to control, $\#p < 0.05$ compared to EGF-treated group.

595

596 **Fig. 6** Western blot analysis showed the amount of p-EGFR relative to α -tubulin in different
597 treatment groups. HuCCA-1 cells were treated with or without anti-EGFR antibody for 2 h
598 prior to exposure to SG for 24 h, and p-EGFR was determined. Results are presented as a
599 mean \pm SEM of triplets independent experiments; $*p < 0.05$ compared to control.

600

601 **Fig. 7** Representative experiments of flow cytometry showing the cell cycle distribution in
602 HuCCA-1 cells. Cells treated with SG or without SG for 24 h and mean percentages of cells
603 in the G₀/G₁, S, and G₂/M phases of cell cycle.

604

605 **Fig. 8** (A) RT-PCR bands showing expression at the transcriptional level of cyclin-D, cyclin-
606 E, cdk-4 and cdk-2 in HuCCA-1 cells after treatment with SG for 24 h. (B) Densitometry
607 values of cyclin-D, cyclin-E, cdk-4 and cdk-2 mRNA relative to GAPDH. Results are
608 presented as a mean ± SEM of triplets independent experiments; **p* < 0.05 compared to the
609 respective control.

610

611 **Fig. 9** (A) Western blot analysis showed the expression of cyclin-D and cyclin-E proteins. (B)
612 The relative expression of cyclin-D and cyclin-E proteins to α -tubulin protein. (C) Western
613 blot analysis showed the expression of P53 and P21 proteins. (D) The relative expression of
614 P53 and P21 proteins to α -tubulin protein. Results are presented as a mean ± SEM of three
615 independent experiments; **p* < 0.05 compared to the respective control.

616

617 **Table 1.** Specific primers and conditions for determination of the expression at the
618 transcriptional level of cyclin-D, cyclin-E, cdk-4 and cdk-2 in HuCCA-1 treated with SG.